Citations

Clear

167 citation(s) found for "Kita, H".

Early Life Represents a Vulnerable Time Window for IL-33–Induced Peripheral Lung Pathology
Drake, Li Y. , Squillace, Diane L., Iijima, Koji, Uchida, Masaru , Kephart, Gail M., Britt, Rodney D. , O’Brien, Daniel R. , Kita, Hirohito , Squillace, Diane, Uchida, Masaru , Britt, Rodney D , O'Brien, Daniel R, Kita, H , Drake, Li , Kobayashi, Takao

Mayo Clinic

The Journal of Immunology | August 30, 2019 | Volume: 203 | Issue: 7 | Pages: 1952-1960

10.4049/jimmunol.1900454 | PMID 31471525 Get It

Abstract IL-33, an IL-1 family cytokine, is constitutively expressed in mucosal tissues and other organs in healthy humans and animals, and expression levels increase in inflammatory conditions. Although IL-33–mediated promotion of type 2 immune responses has been well established, a gap in our knowledge regarding the functional diversity of this pleiotropic cytokine remains. To address this gap, we developed a new IL-33 transgenic mouse model in which overexpression of full-length IL-33 is induced in lung epithelial cells under conditional control. In adult mice, an ∼3-fold increase in the steady-state IL-33 levels produced no pathologic effects in the lungs. When exposed to airborne allergens, adult transgenic mice released more IL-33 extracellularly and exhibited robust type 2 immune responses. In neonatal transgenic mice, up to postnatal day 14, a similar increase in steady-state IL-33 levels resulted in increased mortality, enlarged alveolar spaces resembling bronchopulmonary dysplasia, and altered expression of genes associated with tissue morphogenesis. Processed 25-kDa IL-33 protein was detected in bronchoalveolar lavage fluids without any exogenous stimuli, and pathologic changes were abolished in mice deficient in the IL-33 receptor ST2. These findings suggest that adult lungs are relatively resistant to IL-33 overexpression unless they encounter environmental insults, whereas developing lungs are highly susceptible, with IL-33 overexpression resulting in detrimental and pathologic outcomes.
BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection
Zhu, Bibo , Zhang, Ruixuan, Li, Chaofan , Jiang, Li , Xiang, Min , Ye, Zhenqing , Kita, Hirohito , Melnick, Ari , Sun, Jie , Sun, Jie , Kita, H , Melnick, Ari , Li, Chaofan , Dent, Alexander L.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 28, 2019 | Volume: 116 | Issue: 24 | Pages: 11888-11893

10.1073/pnas.1902310116 | PMID 31138703 Get It

Neutrophils are vital for antimicrobial defense; however, their role during viral infection is less clear. Furthermore, the molecular regulation of neutrophil fate and function at the viral infected sites is largely elusive. Here we report that BCL6 deficiency in myeloid cells exhibited drastically enhanced host resistance to severe influenza A virus (IAV) infection. In contrast to the notion that BCL6 functions to suppress innate inflammation, we find that myeloid BCL6 deficiency diminished lung inflammation without affecting viral loads. Using a series of Cre-transgenic, reporter, and knockout mouse lines, we demonstrate that BCL6 deficiency in neutrophils, but not in monocytes or lung macrophages, attenuated host inflammation and morbidity following IAV infection. Mechanistically, BCL6 bound to the neutrophil gene loci involved in cellular apoptosis in cells specifically at the site of infection. As such, BCL6 disruption resulted in increased expression of apoptotic genes in neutrophils in the respiratory tract, but not in the circulation or bone marrow. Consequently, BCL6 deficiency promoted tissue neutrophil apoptosis. Partial neutrophil depletion led to diminished pulmonary inflammation and decreased host morbidity. Our results reveal a previously unappreciated role of BCL6 in modulating neutrophil apoptosis at the site of infection for the regulation of host disease development following viral infection. Furthermore, our studies indicate that tissue-specific regulation of neutrophil survival modulates host inflammation and tissue immunopathology during acute respiratory viral infection.
Cellular Stress Response to Varicella-Zoster Virus Infection of Human Skin Includes Highly Elevated Interleukin-6 Expression
Jarosinski, Keith W. , Carpenter, John E., Buckingham, Erin M., Jackson, Wallen, Knudtson, Kevin L., Moffat, Jennifer F. , Kita, Hirohito , Grose, Charles , Kita, H

Mayo Clinic

Open Forum Infectious Diseases | May 22, 2018 | Volume: 5 | Issue: 6 | Pages: No page available

10.1093/ofid/ofy118 | PMID 30014002 Get It

Abstract Background The infectious cycle of varicella-zoster virus (VZV) after reactivation from the dorsal root ganglia includes replication and assembly of complete enveloped virions in the human skin to cause the characteristic herpes zoster (shingles). Methods To pursue studies of innate immunity to VZV infection, we have adapted a fetal skin organ culture model to a human neonatal foreskin explant model. Results Abundant expression of VZV IE62, gE, and gC was visualized by confocal microscopy while numerous enveloped virions were observed by electron microscopy in infected skin organ cultures. Microarray experiments demonstrated that the patterns of upregulated transcripts differed between VZV-infected cells and VZV-infected skin explants. One result stood out, namely a >30-fold elevated interleukin (IL)-6 level in the infected skin explant that was not present in the infected monolayer culture. The IL-6 results in the polyermase chain reaction (PCR) assay were reproduced by quantitative PCR testing with newly designed primers. To determine if increased transcription was accompanied by increased IL-6 expression, we quantitated the levels of IL-6 protein in the explant media at increasing intervals after infection. We found a statistically significant increase in IL-6 protein levels secreted into the media from VZV-infected skin explants as compared with mock-infected explants. Conclusions The cellular stress response to VZV infection in neonatal skin explants included highly elevated levels of IL-6 transcription and expression. This skin organ model could be adapted to other viruses with a skin tropism, such as herpes simplex virus.
Eosinophil viability during immunoglobulin-induced degranulation
Weiler, Catherine R., Kita, Hirohito , Hukee, Margaret J., Gleich, Gerald J. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 60 | Issue: 4 | Pages: 493-501

10.1002/jlb.60.4.493 | PMID 8864134 Get It

Abstract Eosinophil adhesion and degranulation appear to be associated with cell death. Eosinophils bound avidly and degranulated with secretory immunoglobulin A (slgA)- and IgG-coupled Sepharose 4B beads but bound poorly and did not degranulate with ovalbumin beads. Through the use of dye staining, we found that about 50% of the bound eosinophils were dead by 4 h, regardless of the protein coating. Colchicine and reduced calcium concentration inhibited binding to beads and eosinophil degranulation in a concentration-dependent manner but did not decrease the percentages of dead bound eosinophils. Electron microscopy showed that eosinophils bound to and spread over bead surfaces. Typical granule exocytosis with release of membrane-free granules occurred in about 20% of bound eosinophils. Eosinophil degeneration and lysis with release of membrane-coated granules occurred in about 50% of bound eosinophils; often only membrane-bound granules were present. Therefore, bound eosinophils degranulate both by classical exocytosis and by release after cytolytic degeneration. By increasing the numbers of bound cells, both IgG and sIgA increase the numbers of dying cells.
Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins
Nakajima, Hirokazu, Loegering, David A., Kita, Hirohito , Kephart, Gail M., Gleich, Gerald J. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 66 | Issue: 3 | Pages: 447-454

10.1002/jlb.66.3.447 | PMID 10496315 Get It

Abstract Use of the murine monoclonal antibodies EG1 and EG2 has been based on the assumption that EG2 recognizes activated eosinophils. We examined the reactivity of EG1 and EG2 with eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and stimulated and nonstimulated eosinophils from normal donors. By radioimmunoassay, EG1 recognized only ECP, whereas EG2 recognized both ECP and EDN. By Western blot, EG1 reacted with ECP, EG2 reacted with both ECP and EDN, but EG2 could not distinguish between lysates of stimulated and nonstimulated eosinophils. By immunofluorescence, EG1 and EG2 at 20 μg/mL stained 95–100% of nonstimulated eosinophils, regardless of fixative; EG1 and EG2 at 0.1 μg/mL stained 61–90% of acetone- and paraformaldehyde-fixed and only 5–21% of methanol-fixed nonstimulated eosinophils. Thus, the reactivity of EG1 and EG2 with eosinophils depends on the method of fixation and antibody concentration; and EG2, in contrast to previous reports, cannot reliably discriminate between resting and activated eosinophils. J. Leukoc. Biol. 66: 447–454; 1999.
Eosinophil granule proteins in peripheral blood granulocytes
Abu-Ghazaleh, R I, Dunnette, Sandra L., Loegering, David A., Checked, James L, Kita, Hirohito , Thomas, Larry L., Gleich, Gerald J. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 52 | Issue: 6 | Pages: 611-618

10.1002/jlb.52.6.611 | PMID 1464733 Get It

Abstract Eosinophils contain four principal cationic proteins, major basic protein (MBP), eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO). To determine the quantities of these proteins in granulocytes and whether they are specific to eosinophils, their concentrations in ly- sates of human granulocytes were measured using specific radioimmunoassays. The effect of different methods for eosinophil lysis on the recovery of the proteins was also studied. Maximal recovery occurred at pH 2 for MBP and pH 5.6 for the other granule proteins. The proteins cosedimented with eosinophils and their concentrations (X ± SEM) in ng/106 eosinophils (and in nM/106 eosinophils) were: MBP, 8,982 ± 611 (641.6); EDN, 3,283 ± 116 (178.4); ECP, 5,269 ± 283 (250.9); and EPO, 12,174 ± 859 (171.5). Basophils from a normal person contained (in ng/106 cells) MBP, 2,374; EDN, 214; ECP, 77; and EPO, 17. Highly purified neutrophils contained (in ng/106 cells) MBP, 3 ± 0.5; EDN, 72 ± 9; and ECP, 50 ± 12. Therefore we conclude that these proteins are mainly expressed in eosinophils, but that certain ones are present in basophils and neutrophils.
Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes
Sur, Sanjiv , Glitz, Dohn G., Kita, Hirohito , Kujawa, Stephen M., Peterson, Ellen A., Weiler, Deborah A., Kephart, Gail M., Wagner, Jill M., George, Terry J., Gleich, Gerald J. , Leiferman, Kristin M. , Kita, H

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 63 | Issue: 6 | Pages: 715-722

10.1002/jlb.63.6.715 | PMID 9620664 Get It

Abstract Eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are generally regarded as eosinophil-specific proteins. We tested whether EDN and ECP are present in mature neutrophils. By indirect immunofluorescence, both eosinophils and neutrophils stained with antibodies to EDN and ECP. Lysates of purified (<0.1% eosinophil contamination) neutrophils contained EDN, 112 ± 4 ng/106 cells, and ECP, 163 ± 2 ng/106 cells, whereas eosinophil major basic protein (MBP) was not detectable. Electron microscopic examination of immunogold-labeled buffy coat cells stained with EDN antibody showed that EDN is localized to neutrophil granules. Finally, EDN mRNA was detected in lysates of highly purified neutrophils (0.001% eosinophil contamination) by the reverse transcription-polymerase chain reaction. We conclude that proteins that are either identical to or immunologically cross-reactive with EDN and ECP are present in neutrophils and that EDN is synthesized and localized to neutrophil granules. Thus, caution must be exercised in interpreting the presence of EDN and ECP as specific markers of eosinophil-associated inflammation in human disease.
IL-33–Responsive Group 2 Innate Lymphoid Cells Are Regulated by Female Sex Hormones in the Uterus
Bartemes, Kathleen R. , Iijima, Koji, Drake, Li Y. , Kita, Hirohito , Chen, Chien-Chang, Drake, Li , Kita, H , Chen, Chien‐Chang

Mayo Clinic

The Journal of Immunology | November 13, 2017 | Volume: 200 | Issue: 1 | Pages: 229-236

10.4049/jimmunol.1602085 | PMID 29133293 Get It

Abstract Group 2 innate lymphoid cells (ILC2s) reside in multiple organs in the body, where they play roles in immunity, tissue homeostasis, and metabolic regulation. However, little is known about the regulatory mechanisms of ILC2s in different organs. Here, we identified ILC2s in the mouse uterus and found that they express cell surface molecules, including the IL-33 receptor, ST2, that are roughly comparable to those expressed by lung ILC2s. Both in vivo and in vitro treatment with IL-33 induced type 2 cytokine production in uterine ILC2s, suggesting that they respond to IL-33 in a manner similar to ILC2s in other organs. Importantly, uterine ILC2s were nearly absent in ovariectomized mice and were increased in wild-type mice by estrogen administration, whereas lung ILC2s were unaffected by both ovariectomy and estrogen administration. Likewise, a marked reduction in uterine ILC2s was observed in mice deficient in estrogen receptor α or estrogen receptor β. Furthermore, uterine ILC2s highly expressed estrogen receptor α, and in vitro culture of isolated uterine ILC2s with 17β-estradiol modified expression of a number of genes. Finally, an increased prevalence in neonatal mortality was observed in litters from dams lacking the IL-33 receptor, ST2. Taken together, our findings indicate that unlike lung IL2Cs, uterine ILC2s are regulated by female sex hormones, which may specialize them for specific physiological functions.
CELLULAR SENESCENCE DRIVES FIBROTIC PULMONARY DISEASE
White, Thomas A. , Iijima, Koji, Mazula, Daniel L., Passos, JF, Kirkland, James L. , Schafer, Marissa , Kita, Hirohito , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | July 1, 2017 | Volume: 1 | Issue: suppl_1 | Pages: 135-135

10.1093/geroni/igx004.547 Get It

IL ‐33: biological properties, functions, and roles in airway disease
Kita, Hirohito , Drake, Li Yin, Kita, H , Drake, Li Y.

Mayo Clinic

Immunological Reviews | June 28, 2017 | Volume: 278 | Issue: 1 | Pages: 173-184

10.1111/imr.12552 | PMID 28658560 Get It

Summary Interleukin ( IL )‐33 is a key cytokine involved in type 2 immunity and allergic airway diseases. Abundantly expressed in lung epithelial cells, IL ‐33 plays critical roles in both innate and adaptive immune responses in mucosal organs. In innate immunity, IL ‐33 and group 2 innate lymphoid cells ( ILC 2s) provide an essential axis for rapid immune responses and tissue homeostasis. In adaptive immunity, IL ‐33 interacts with dendritic cells, Th2 cells, follicular T cells, and regulatory T cells, where IL ‐33 influences the development of chronic airway inflammation and tissue remodeling. The clinical findings that both the IL ‐33 and ILC 2 levels are elevated in patients with allergic airway diseases suggest that IL ‐33 plays an important role in the pathogenesis of these diseases. IL ‐33 and ILC 2 may also serve as biomarkers for disease classification and to monitor the progression of diseases. In this article, we reviewed the current knowledge of the biology of IL ‐33 and discussed the roles of the IL ‐33 in regulating airway immune responses and allergic airway diseases.